- Residency, Ophthalmology, University of Rochester
- Fellowship, Retina Clinical & Research, Massachusetts Eye & Ear Infirmary
- MD, Medicine, SUNY Downstate Medical Center College of Medicine
Biomedical Engineering, Experimental Pathology, Immunology, Microbiology, Neuroscience
Understanding the Molecular Basis of Macular Degeneration in Order to Hasten the Eradication of Blindness
Alu RNA transcripts promote advanced dry age-related macular degeneration:
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration and is a leading cause of blindness in the Unites States. Currently, there is no FDA approved therapy for the over 1 million Americans with GA. One major goal of the laboratory was to identify novel molecular targets to fight this major unmet health need. We recently identified a class of RNA molecules - Alu RNA transcripts - cause RPE degeneration, which is a critical step in the pathogenesis of GA (Kaneko et al., Nature 2011). We further identified a new protective role for the enzyme Dicer1 whereby it cleaves Alu RNA transcripts, rendering them innocuous. In GA, the abundance of Dicer1 is reduced which leads to accumulation of cytotoxic Alu RNAs and RPE degeneration. This work was highlighted by commentaries in Cell (2011) and Nature (2011), and will serve as the foundation for the rational design of therapeutics for treating this pervasive disease.
Vascular Heterogeneity in the Eye:
The main goal of the laboratory is to elucidate molecular mechanisms that fundamentally regulate vascular growth in normal and diseased states in the eye. In 2006, we answered the foremost outstanding question in vascular biology: "What is responsible for avascularity of the cornea?" This work (Ambati et al., Nature 2006) demonstrated that, contrary to prevailing dogma that a multitude of anti-angiogenic molecules was required for corneal avascularity, a single protein - soluble VEGF receptor-1 - was uniquely responsible. This work was hailed by Science as a Signaling Breakthrough of the Year (Adler et al., Science STKE 2007), and is far-reaching because the cornea is the default platform for testing therapies for cancer, atherosclerosis, and other diseases driven by angiogenesis. In 2009 this work was extended to the lymphatic vasculature with our discovery and characterization of a similar, soluble, splice variant of VEGF receptor-2 (Albuquerque et al., Nature Med 2009) which sequesters VEGF-C and is responsible, specifically, for the alymphatic cornea.
Paradigms in Ocular Angiogenesis:
Several corneal and retinal diseases are hallmarked by neovascularization that often leads to irreversible blindness. We seek to identify the specific mediators for such pathologic responses in order to develop targeted therapeutics to reverse and prevent these devastating disorders. Our laboratory was the first to demonstrate the presence of in situ complement activation in the retina and choroid of patients with age-related macular degeneration (AMD). We showed (Nozaki et al., PNAS 2006) that this complement activation triggers the angiogenic switch that transforms the disease state from an atrophic to a neovascular phenotype. This vital observation has now resulted in the initiation of pre-clinical/Phase I clinical trials of complement inhibitors in AMD by more than a dozen pharmaceutical/biotech companies. Crucial to this translational advance was our labs report of the first animal model of AMD (Ambati et al., Nature Med 2003). This data in conjunction with several other studies has supported a major paradigm shift towards inflammatory and immunologic mediators playing a significant role in the development of AMD and its progression to choroidal neovascularization.
The Interface of Immunity and Vascular Response in the Eye:
How does the omnipresent immune system induce pathologic vascular responses in the eye? Given the fundamental lack of knowledge on the molecular basis of immune regulated angiogenesis, our lab is committed to unraveling these complex biologic interactions. We recently identified (Kleinman et al., Nature 2008) the immune receptor TLR3 as a surprising signaling receptor for small interfering RNAs (siRNAs) in a sequence-independent manner. We showed that siRNAs "generically" suppress angiogenesis in multiple mouse models by activating cell surface TLR3 rather than by triggering RNA interference. These findings, which were covered in commentaries by Nature Medicine (2008) and Nature Biotechnology (2008), advance the nascent understanding of the multifunctional aspects of the immune system within the eye. We will continue our investigations into immunovascular biology with the goal of mapping this critical interface while creating more effective and tolerable medicines to treat neovascular diseases.
Our lab made a major breakthrough in this field by identifying CCR3, a chemokine receptor which has been implicated to be a key player in allergic inflammatory processes, as a biomarker and potential therapeutic target for choroidal neovascularization in age related macular degeneration (Takeda et al., Nature 2009). Of special importance, we were able to detect abnormal blood vessels in vivo in the eyes of mice that spontaneously develop CNV, prior to invasion of the retina, by attaching anti-CCR3 antibodies to tiny semiconductor nanocrystals, or "quantum dots." The discovery of this target may some day enable detection and treatment of neovascular age-related macular degeneration before blood vessels invade the retina and damage eyesight.